- New alliance will crack down on adulterated products touting dietary supplement claims
- UnitedHealth: Cost of diabetes could be $3.35 trillion by 2020
- FDA approves test to monitor levels of Zortress in the bloodstream
- FDA approves Merck's Gardasil for prevention of anal cancer
- K-V: FDA will approve Gestiva by PDUFA date
SILVER SPRING, Md. — The Food and Drug Administration has approved a new formulation of a cancer drug made by Novartis for a type of brain tumor in children, the agency said.
The FDA announced the approval of Afinitor Disperz (everolimus) tablets for oral suspension to treat a rare brain tumor called subependymal giant-cell astrocytoma, or SEGA. The agency said Afinitor Disperz, a new dosage form of the drug Afinitor, is the first pediatric-specific dosage form for a pediatric tumor to receive FDA approval.
The drug, designed to dissolve in water, is recommended for patients aged 1 year and older with tuberous sclerosis complex who are diagnosed with SEGA that can't be treated with surgery. TSC is a rare genetic disease that causes tumors to grow in the brain and other vital organs, while SEGA is a slow-growing tumor that can cause life-threatening complications by blocking the flow of blood to the brain, occurring in 6-9% of TSC patients.